Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

IL-15 has potential as an immunotherapeutic agent for cancer treatment because it is a critical factor for the proliferation and activation of natural killer (NK) and CD8⁺ T cells. Administration of anti-CD40 antibodies has shown anti-tumor effects in vivo through a variety of mechanisms. Furthermor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2009-05, Vol.106 (18), p.7513-7518
Hauptverfasser:	Zhang, Meili, Yao, Zhengsheng, Dubois, Sigrid, Ju, Wei, Müller, Jürgen R, Waldmann, Thomas A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antibodies Antibodies, Monoclonal - therapeutic use Antineoplastic Protocols Biological Sciences CD40 Antigens - antagonists & inhibitors Cell Line, Tumor Colonic Neoplasms - drug therapy Colonic Neoplasms - therapy Colorectal cancer Combined Modality Therapy Cytokines Cytotoxicity, Immunologic Disease Models, Animal Immune system Immunotherapy Interleukin-15 - therapeutic use Interleukin-15 Receptor alpha Subunit - biosynthesis Kidney cells Killer Cells, Natural - immunology Lymphocyte Activation Medical treatment Mice Mice, Inbred C57BL Natural killer cells Natural killer T cells Receptors Rodents T lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!